What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence indicates that benralizumab is non-inferior to mepolizumab in terms of remission rates, with an adjusted remission rate of 57.7% for benralizumab compared to 56.5% for mepolizumab. However, the lack of direct comparisons with standard care alone and the reliance on indirect treatment comparisons introduce uncertainty. Therefore, while the efficacy is comparable, it does not demonstrate a clear edge over existing treatments.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for benralizumab fall within the acceptable range for NHS resources, with the committee concluding that the ICER is defensible. The economic model suggests that the treatment provides good value for money, particularly given the innovative nature of the therapy and the significant burden of the disease.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee acknowledged that benralizumab could significantly improve quality of life by reducing the need for oral corticosteroids, which are associated with severe side effects. Patient testimonials indicated substantial improvements in daily functioning and well-being after treatment. However, the evidence from the MANDARA trial was not fully aligned with real-world experiences, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Benralizumab has a favorable safety profile, with adverse events primarily being mild to moderate. The committee noted that the treatment could reduce the severe side effects associated with long-term corticosteroid use, which is a significant advantage. Serious adverse events were rare, supporting a strong tolerability profile.
Was the drug compared against what payers expect? — Comparator Selection
The evidence primarily compares benralizumab with standard care, which includes oral corticosteroids and immunosuppressants. While this is appropriate for the non-severe population, the absence of direct comparisons with severe treatment options like cyclophosphamide or rituximab limits the robustness of the evidence. The indirect comparisons used were deemed acceptable but not ideal.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included adults with relapsing or refractory EGPA, which is representative of the intended patient population. The committee noted that while some patients with severe EGPA were excluded, the treatment could still be applicable to them once their condition stabilizes, enhancing generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Benralizumab can be integrated into existing treatment pathways with minimal disruption. The treatment is an add-on to standard care, which is already established in clinical practice. Minor adjustments may be needed for administration, but overall, it fits well within current treatment frameworks.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of benralizumab is manageable, and the treatment is expected to provide net savings by reducing the need for corticosteroids and associated adverse effects. The committee concluded that the resource implications are justifiable given the expected health benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base includes a phase 3 trial (MANDARA) and indirect comparisons, which provide a reasonable level of confidence in the findings. However, the reliance on indirect comparisons and the exclusion of severe cases introduce some limitations, preventing a higher rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the long-term effects and the generalizability of the trial results, the committee noted that the treatment addresses a significant unmet need in a rare condition. The context of the disease and the innovative nature of the therapy help mitigate some of the uncertainties.
